Professor John McLauchlan, the University of Glasgow
My name is John McLauchlan and I am from the University of Glasgow and I work at the MRC Centre for Virus Research. I am one of the founding partners for STOP-HCV and this brings together a number of academic groups and industrial partners to really try to address key questions in treating patients with Hepatitis C and primarily to see what the best treatment options are for these patients so they can clear the virus.
So in Glasgow, what we have been doing is really cooperating with the other sites in a number of different ways and one of them is that I am one of the co-Chairs on an another Consortium called HCD Research UK which underpins much of the work that is being carried out by STOP-HCV.
As well as that, what we in Glasgow is very much along with our partners in Oxford and in Public Health England is to look at new ways to try and look at the resistance that might develop in patients who are treated with new therapies. So this becomes important in trying to identify which patients would receive better treatments and moving towards areas of thinking about patients who need to be re-treated so these are patients in whom the drugs have not managed to clear the virus and what we are trying to do is entirely optimise the kind of therapies which those patients now should be given so that they will go on to clear the virus.